Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to issue its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($2.01) per share and revenue of $244.3320 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share for the quarter, beating the consensus estimate of ($3.48) by $1.58. The business had revenue of $212.80 million during the quarter, compared to the consensus estimate of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The business’s quarterly revenue was up 1357.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($7.10) earnings per share. On average, analysts expect Madrigal Pharmaceuticals to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Madrigal Pharmaceuticals Price Performance

Shares of MDGL stock opened at $415.95 on Thursday. The company has a market capitalization of $9.23 billion, a PE ratio of -32.37 and a beta of -1.02. The firm has a fifty day simple moving average of $428.62 and a 200-day simple moving average of $346.46. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17. Madrigal Pharmaceuticals has a twelve month low of $200.63 and a twelve month high of $463.63.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, Director Paul A. Friedman sold 129,172 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $370.24, for a total transaction of $47,824,641.28. Following the sale, the director directly owned 187,164 shares of the company’s stock, valued at approximately $69,295,599.36. This represents a 40.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William John Sibold sold 7,279 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $445.63, for a total transaction of $3,243,740.77. Following the sale, the chief executive officer directly owned 102,474 shares in the company, valued at $45,665,488.62. This trade represents a 6.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 165,683 shares of company stock valued at $61,921,142 and sold 248,642 shares valued at $91,388,103. 21.50% of the stock is currently owned by company insiders.

Institutional Trading of Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Kestra Investment Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth $85,000. Hsbc Holdings PLC acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $309,000. Brevan Howard Capital Management LP acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $353,000. Man Group plc acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $414,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $418,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. UBS Group reaffirmed a “buy” rating and issued a $523.00 price target (up from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 12th. Oppenheimer upped their price target on shares of Madrigal Pharmaceuticals from $500.00 to $590.00 and gave the company an “outperform” rating in a report on Friday, October 10th. TD Cowen upped their price target on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. B. Riley upped their price target on shares of Madrigal Pharmaceuticals from $460.00 to $560.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a report on Thursday, September 4th. They issued a “buy” rating and a $500.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $532.70.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.